MAPT and Alzheimer disease: Early AD diagnoses are most commonly made on purely clinical grounds or with additional ancillary testing including MRI imaging, neuropsychological testing, CSF analysis for amyloid and tau proteins, and PET imaging (either metabolic or specifically for amyloid or tau; Albert et al., 2011).